PSG Club Value & Squad Cost More Than Double That Of Champions League Opponents Inter Milan
PSG Club Value & Squad Cost More Than Double That Of Champions League Opponents Inter Milan
The squad cost of PSG is more than double that of their Champions League final opponents Inter Milan.
This is highlighted in today's print edition of Turin-based newspaper Tuttosport, via FCInterNews.
Paris Saint-Germain are in the Champions League final. This is the second final in their history.
Advertisement
And winning Europe's biggest prize has always been the biggest objective for PSG since their Qatari takeover in 2011.
Qatari Emir Tamim Al Thani bought PSG in 2011 for €100 million. The Qatari ownership has invested €1.3 billion in the club since then, the Gazzetta note.
PSG's commercial profile has grown enormously under its present ownership.
From the arrival of big name players to the high profile partnership with Nike Jordan, the value of the French club has risen to €3.8 billion according to Football Benchmark.
Meanwhile, Football Benchmark value PSG's Champions League final opponents Inter at €1.7 billion under Oaktree Capital.
PSG Squad Cost More Than Double That Of UCL Final Opponents Inter Milan
MILAN, ITALY – MAY 22: (L-R) CEO Corporate FC Internazionale Alessandro Antonello, Oaktree's Global Opportunities strategy Managing Director Katherine Ralph, Managing Director and Co-Head of Europe for Oaktree's Global Opportunities strategy Alejandro Cano, CEO Sport FC Internazionale Giuseppe Marotta attend a meeting between FC Internazionale new owners Oaktree and Club's Management on May 22, 2024 in Milan, Italy. (Photo by Guido)
Then, there is the big disparity in the squad costs of PSG and Inter Milan respectively.
Advertisement
PSG's squad cost between rages and transfer fee amortization comes to €790 million for the 2023-24 season, notes the Gazzetta.
Meanwhile, for Inter, that figure stands at €309 million.
On wages alone, PSG spent a total of €659 million last season. Meanwhile, for Inter that figure was €257 million.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
.jpg&w=3840&q=100)
Vogue
22 minutes ago
- Vogue
Jonathan Anderson Has Been Appointed Sole Creative Director of Dior
Can Anderson recreate the same magic at Dior? After years of tremendous growth — revenue went from €2.2 billion in 2017 to €9.5 billion in 2023, according to HSBC estimates — Dior has been hit by the luxury downturn and global turmoil. Sales decreased to €8.7 billion in 2024, per HSBC. In the first quarter, sales of LVMH's fashion and leather goods division were down 5 per cent, positioning the group's fashion business in the middle of a polarised market. 'Dior has to be revived,' Solca told Vogue Business back in April. Jonathan Anderson's Spring/Summer 2025 show for Loewe received a standing ovation from many of his peers as well as Arnault. Photo: Isidore Montag / Anderson's Spring/Summer 2024 for his namesake brand JW Anderson featured hoodies and shorts molded from plasticine. Photo: Filippo Fior / The house now appears to have everything in place for a revival. It recently hired Pierre-Emmanuel Angeloglou as deputy CEO in April, after poaching Miu Miu CEO Benedetta Petruzzo in October to be its managing director. Both executives report to Arnault. Anderson, who has a reputation as a hard-working and brilliant designer, surely has the ability to blend in with the Dior DNA, juggling its strong heritage and codes. 'Ever since he started working on menswear back in February, he's been spending a lot of time in the archives looking at all the different elements of the brand that the different designers at its helm over the years have developed — like Christian Dior or Yves Saint Laurent, John Galliano, Raf Simons,' Arnault says. Besides facing the challenge of working across men's and women's lines, Anderson will also earn his couture stripes as Dior is among the handful of houses to have turned couture into a thriving business. And while he hasn't been at a couture house before, Anderson is known for his conceptual shows and couture spirit, especially visible in his SS25 show, which featured 'reimagined French golden age couture dresses, all hoops and semi-sheer flower prints', as Vogue Runway's Sarah Mower described them. The fashion world will have to wait until January 2026 to see Anderson's first couture designs for Dior, as the house is going to skip the couture season in July. 'Maria Grazia had 20 couture dresses in her cruise show, which have kept the atelier busy,' Arnault says. Arnault also confirmed that Anderson's first women's show for Dior will be during the all-important September season. 'In the 25 years I've been working in fashion, there have never been so many creative changes,' she muses. 'We will see the visions of so many different artistic directors for the industry. I think it's going to bring up a lot of emotion and excitement. And that's what fashion is about.' Anderson will find himself head-on with Matthieu Blazy at Chanel, alongside a number of other high-stake debuts. Anderson's first menswear show for Dior will be in June, as previously reported. Would Dior ever stage co-ed? 'I think for the time being we're going to keep it separate. You never know what can happen, but we don't have any plans to reduce the number of shows,' Arnault replies. What about JW Anderson — will he be staying at the helm? 'It's his namesake brand, so obviously it is a project that is really important to him. Yes, he's going to stay involved in JW Anderson, but maybe in a different way. I think this would be more of a question for him.' Watch this space.
Yahoo
23 minutes ago
- Yahoo
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients," said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. "These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition studyPSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
24 minutes ago
- Entrepreneur
Doing nothing is still doing something
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Every week, I speak to people who've just sold a business, inherited a lump sum, or hit a major milestone. Suddenly, they're staring at a big question. What should I do with this money? More often than not, their answer is nothing. In a world that feels defined by rolling uncertainty – from elections to interest rates, inflation to geopolitical unrest – many smart, accomplished individuals convince themselves that pressing pause is the prudent move. They tell themselves they'll wait for the next election, the next Bank of England announcement, or until the latest crisis in the Middle East or the US blows over. But here's the uncomfortable truth, doing nothing is still doing something – and very often, it's the wrong thing. We saw this play out at the start of the year when Donald Trump's likely return to the White House and the prospect of fresh tariffs sent ripples through global markets. Investors froze, and while the tariffs have been shelved (for now), the real damage had already been done – not to portfolios, but to behaviour. This is decision paralysis in action. And in my experience, it's most acute among entrepreneurs and high-net-worth individuals post-exit, many of whom are navigating wealth independently for the first time. It's human nature to crave certainty, especially when it comes to money, but if you're waiting for a time when everything is calm, clear, and safe before investing or making a financial decision, I've got bad news – that day is never going to arrive. Markets move, the political climate is noisy, the global economy is always in flux. If you're frozen by fear, your money isn't standing still – it's slipping backwards. One former client sold down their pension right before the Brexit vote, convinced markets would crash. The market dipped, briefly, then bounced. By the time they tried to get back in, they'd missed the rebound and locked in the loss. Others are still on the sidelines, holding out for the 'right time'. Meanwhile, the market has delivered double-digit returns. High interest rates have only added to the inertia. Plenty of people are sitting on cash, happy to earn 5% in the bank. But if you're a higher-rate taxpayer, you're pocketing closer to 2.5% – less than inflation – and over time, your 'safe' money is shrinking in real terms. Global Equities, by contrast, are up 11% over the past year – despite all the turmoil around tariffs. This hesitation isn't limited to financial investments either, we're seeing the same reluctance around property purchases. Entrepreneurs are delaying buying homes or commercial units in the hope that mortgage rates will fall or prices will soften. However, unless you have a crystal ball, trying to time the market is a game you're unlikely to win. If you've found a property that suits your needs and budget, and you can afford it, the best decision is to buy it. Your home is where you live, not a speculative asset to be perfectly timed. There's immense freedom in simply making a decision. It takes the weight off your mind and gives you back your mental bandwidth – something every founder or investor will recognise as valuable in its own right. Doing nothing might feel like the safe bet, but inaction can be far more damaging than a well-informed choice. And contrary to popular belief, you don't need to have all the answers today. What you do need is a plan. Even a basic plan creates structure, helps you map the road ahead, and protects you from making knee-jerk decisions driven by fear or headlines. Here's how to break free from the grip of decision paralysis: Zoom out: Focus on your long-term objectives, rather than tomorrow's headlines. What do you want your money to do for you over the next 10, 20, 30 years? Separate fact from fear: Emotions often drive poor decisions. If you find yourself saying "I'll just wait until…", ask whether that's a rational strategy or an emotional deflection. Get advice: A good financial planner will help you understand your goals, cut out the noise, and navigate complexity with clarity. Act with intent: Even small, deliberate steps can make a difference. Wealth isn't built from the sidelines. Entrepreneurs are used to taking calculated risks, but when it comes to managing post-exit wealth or personal finances, many find themselves out of their depth. A little knowledge can be a dangerous thing – and half-understanding the tax system, the economy, or the markets can lead to costly mistakes. That's why it's so important to talk to someone. Burying your head in the sand is not a wealth strategy. The economy will always feel volatile, but the people who do best are those who act with confidence and intention – no matter the noise. You don't need to get every decision right, but you do need to make a decision. Inaction is a choice, and often, it's the most expensive one of all.
